1. AB1182 Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis. (23rd January 2014) Authors: Ruperto, N.; Brunner, H.; Quartier, P.; Constantin, T.; Wulffraat, N.; Horneff, G.; Brik, R.; McCann, L.; Kasapcopur, O.; Rutkowska-Sak, L.; Schneider, R.; Berkun, Y.; Calvo, I.; Erguven, M.; Goffin, L.; Hofer, M.; Kallinich, T.; Knupp, S.; Uziel, Y.; Viola, S. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB1186 IL-1beta inhibition with canakinumab in patients with systemic juvenile idiopathic arthritis: Efficacy and safety outcomes from a single-dose, placebo-controlled study. (23rd January 2014) Authors: Quartier, P.; Erguven, M.; Horneff, G.; Berkun, Y.; Lheritier, K.; Kim, D.; Abrams, K.; Constantin, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients. (10th June 2014) Authors: Quartier, P.; Grom, A.; Ruperto, N.; Brunner, H.; Schikler, K.; Erguven, M.; Goffin, L.; Hofer, M.; Kallinich, T.; Marzan, K.; Gaillez, C.; Lheritier, K.; Abrams, K.; Martini, A.; Lovell, D. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗